Virtual City-Wide Medical Grand Rounds: Neuroprotection therapies for Parkinson's disease: "One drug does not fit all"
Neuroprotection therapies for Parkinson's disease: “One drug does not fit all”
Anthony E. Lang, OC, FRCPC, FAAN, FCAHS, FRSC
Director, Edmond J. Safra Program in Parkinson’s Disease, the Morton and Gloria Shulman Movement Disorders Clinic and the Rossy Progressive Supranuclear Palsy Centre, Toronto Western Hospital, University Health Network and the University of Toronto
Lily Safra Chair in Movement Disorders, University Health Network
Jack Clark Chair for Parkinson’s Disease Research, University of Toronto
Senior Scientist, Krembil Brain Institute, University Health Network
Principle Investigator, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto
At the end of the presentation, participants should be able to:
- Explain the basis for considering one drug vs combination therapy in disease modification for Parkinson’s disease,
- Recognize the broad heterogeneity of Parkinson’s disease and explain possible reasons for this,
- Explain the various different proposed mechanisms underlying Parkinson’s disease pathogenesis,
- Debate reasons for thinking that Parkinson’s disease represents a single vs multiple diseases, and
- Propose reasons for considering the use of multiple drugs in disease modification and how these might be studied with respect to drug development and clinical trials.
Accreditation (live event only):
City Wide Medical Grand Rounds is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.
Evaluation & Attendance:
Attendance for Maintenance of Certification credit will only be tracked if evaluation and attendance surveys are completed.